For type 2 diabetes mellitus. ANDA 205994, held by Glenmark Pharmaceuticals. Saxagliptin Hydrochloride.
As of Nov 21, 2026, ANDA 205994 (Saxagliptin), held by Glenmark Pharmaceuticals, was first approved by FDA on Jul 31, 2023, with 0 approved supplements and 0 published complete response letters.
Saxagliptin tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of use:
| Jul 31, 2023 | Original application | Approved | None posted |
| Feb 15, 2023 | Original application | Tentative approval | None posted |
| SaxagliptinEQ 2.5MG BASE · tablet;oral | Saxagliptin Hydrochloride | Rx |
| SaxagliptinEQ 5MG BASE · tablet;oral | Saxagliptin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters